Athira Pharma, Inc. is advancing a novel, potentially transformative approach for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Unlike other products approved and in ...

Athira Pharma said on Tuesday its drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease. March 30, 2022.

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for Alzheimer's disease, failed in a Phase 2/3 trial, prompting at least two Wall ...

As a child, Athira Geetha used to write down stories and poems as a pastime. In her debut poetry book, 'Tangled Thoughts in Motion' (published by Partridge India), Geetha wrote what she knew ...

Athira had clung to the hope that its experimental drug fosgonimeton could overcome a phase 2 failure in Alzheimer’s to demonstrate success in Parkinson’s and dementia. Unfortunately, a mid ...

Athira priced its IPO on Thursday at $17 per share, which came in at the high end of its range.The company sold 12 million shares and raised $204 million in the IPO. The stock was up slightly in ...